Free Biopharma Daily Stock Updates - 03/19/21

BPIQ
Mar 19, 2021
1 min read

$XBI $145.07 +3%

Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here !

Pipeline Updates

$CLVS +45% Presented data from ARIEL4 study, a ph 3 study of Rubraca for patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation who have received two or more prior lines of chemotherapy. The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus chemotherapy. source

$IDRA -62% Failed pivotal ph 2 ILLUMINATE-301 trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma. source

$XBI $145.07 +3%

Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Pipeline Updates

Comments

Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here !